Psoriatic News and Research

RSS

Scientists discover a key starting point for inhibiting inflammation in psoriasis and psoriatic arthritis

Around 250,000 people in Austria suffer from psoriasis. One third of them develop inflammation in their joints (psoriatic arthritis) as a result of the chronic skin condition.

6 Jul 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

27 Jun 2022

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.

13 Jun 2022

New AI tool can speed up the diagnosis of psoriatic arthritis by up to 4 years

Researchers in Israel have shown that a new machine-learning tool can speed up the diagnosis of psoriatic arthritis (PsA) by up to 4 years, potentially preventing irreversible joint damage and deteriorating function for sufferers.

15 May 2022

NYU Langone joins NIH-sponsored program as leading center to discover new targets for autoimmune, inflammatory diseases

NYU Langone Health is joining a new National Institutes of Health (NIH)-sponsored program called Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) as a leading center to discover new targets for therapy in these diseases.

30 Mar 2022

Updated guideline released for managing antirheumatic drugs in patients undergoing hip or knee replacement

The American College of Rheumatology and the American Association of Hip and Knee Surgeons released a summary of their updated guideline for the Perioperative Management of Antirheumatic Medication in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.

28 Feb 2022

Use of immunosuppressants for inflammatory rheumatic diseases and the associated risk of severe COVID-19

A recent study posted to the medRxiv* preprint server investigated the risk of severe/fatal coronavirus disease 2019 (COVID-19) in patients treated with immunosuppressants for inflammatory rheumatic diseases (IRD).

15 Feb 2022

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

A survey demonstrated that patients with systemic autoimmune rheumatic diseases commonly experience augmented disease severity and disrupted treatment regimens of disease-modifying antirheumatic drugs after acute COVID-19 course.

11 Feb 2022

Study identifies several proteins that protect against disease development

Inflammatory processes are associated with a large range of human diseases, including rheumatic diseases and allergies. Protein biomarkers are measurable molecules that can have a prognostic value in patients, be used to diagnose disease, or indicate severity of disease.

8 Dec 2021

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

Despite clear directives outlined in the updated guidelines published by the American College of Rheumatology/National Psoriasis Foundation (ACR/NPF) in 2018, there is limited data regarding medication use in real-world clinical practice and patient medication preferences for the treatment of psoriatic arthritis (PsA).

9 Nov 2021

Study shows significant decreases in infections among people with psoriatic arthritis

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows significant decreases in infections among people with psoriatic arthritis over the years 2012-2017.

2 Nov 2021

Researchers identify mechanism behind insufficient treatment efficacy of psoriasis drugs

Interleukin-12 - a messenger molecule of immune cells - was long considered to trigger the development of psoriasis.

22 Oct 2021

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data looking at biologic treatment and vaccine hesitancy in psoriasis patients is being presented today at EADV’s 30th Congress.

1 Oct 2021

Scientists discover new cell type in human skin that contributes to inflammatory skin diseases

A team of international scientists and clinical experts have unraveled a new cell type in human skin that contributes to inflammatory skin diseases such as atopic dermatitis (AD) and psoriasis (PSO). Their study findings were published in the Journal of Experimental Medicine in September 2021.

17 Sep 2021

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

Researchers in the UK have conducted a large population-based study showing that people with immune-mediated inflammatory diseases (IMIDs) appear to be at an increased risk of serious outcomes from coronavirus disease 2019 (COVID-19).

14 Sep 2021

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

A new clinical trial to determine whether a third dose of vaccine will improve the immune response for people who have weakened immune systems is launching in the UK.

24 Aug 2021

Targeting a skin protein may reduce the severity of psoriasis, study reveals

Results from a Michigan Medicine study reveal that targeting a protein found in the skin may reduce the severity of psoriasis.

12 Aug 2021

Investigational treatment improves survival rate of babies lacking thymus

An investigational treatment pioneered by a Duke Health pediatrician resulted in a one-year survival rate of 77% among children born with a rare condition in which they lack an immune system.

4 Aug 2021

EULAR Patient Research Partners join in new research project to advance treatment of psoriatic arthritis

Eleven Patient Research Partners (PRPs) from three organizations (EULAR, GRAPPA-EU, and EUROPSO) participate in the new research project HIPPOCRATES, ensuring the patients' perspective is preserved and prioritized in all research activities to maximize the project's impact.

2 Jul 2021

Psoriatic News and Research

Scientists discover a key starting point for inhibiting inflammation in psoriasis and psoriatic arthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

New AI tool can speed up the diagnosis of psoriatic arthritis by up to 4 years

NYU Langone joins NIH-sponsored program as leading center to discover new targets for autoimmune, inflammatory diseases

Updated guideline released for managing antirheumatic drugs in patients undergoing hip or knee replacement

Use of immunosuppressants for inflammatory rheumatic diseases and the associated risk of severe COVID-19

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

Study identifies several proteins that protect against disease development

HSS study provides insight into real-world medication use for treatment of psoriatic arthritis

Study shows significant decreases in infections among people with psoriatic arthritis

Researchers identify mechanism behind insufficient treatment efficacy of psoriasis drugs

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Scientists discover new cell type in human skin that contributes to inflammatory skin diseases

Immune-mediated inflammatory disease may increase risk of severe COVID-19 outcomes

New clinical trial to test third dose of COVID-19 vaccine for immunocompromised people

Targeting a skin protein may reduce the severity of psoriasis, study reveals

Investigational treatment improves survival rate of babies lacking thymus

EULAR Patient Research Partners join in new research project to advance treatment of psoriatic arthritis

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News